INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
SEC FORM 4/Grant or awardVerified data

Lundquist Kevin Michael reported OTLK

Chief Financial Officer · Outlook Therapeutics, Inc. · Outlook Therapeutics, Inc. — Employee Stock Option (Right to Buy)

Side
A
Value
—
Shares
500.0K
Price
—
Executed
Sep 1, 2026
Disclosed
Sep 2, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Sep 1 executedSep 2, 2026 disclosed

OTLK · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · OTLK

    No records

    No other disclosures for this security in the dataset.

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002074701-26-000005
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 1, 2026
    Published
    Sep 2, 2026
    Ingested by INSIDER
    Nov 5, 02:19 UTC
    Last re-read
    Nov 5, 02:19 UTC

    Extracted facts

    Filer
    Lundquist Kevin Michael
    Role
    Chief Financial Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Outlook Therapeutics, Inc. — Employee Stock Option (Right to Buy)
    Ticker
    OTLK
    Shares
    500.0K
    Price per share
    $0
    Execution date (reported)
    Sep 1, 2026
    Owned after transaction
    500.0K shares
    Days from execution to publication
    1

    What this establishes

    Lundquist Kevin Michael filed this Form 4 reporting a grant or award of OTLK on Sep 1, 2026. It became public on Sep 2, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Lundquist Kevin Michaelcik:0002074701
    Issuer
    Outlook Therapeutics, Inc.cik:0001649989

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.